MCID: ATS001
MIFTS: 63

Autistic Disorder

Categories: Mental diseases, Genetic diseases

Aliases & Classifications for Autistic Disorder

MalaCards integrated aliases for Autistic Disorder:

Name: Autistic Disorder 38 12 24 42 14 69
Autism 12 24 29 3
Autistic Disorder of Childhood Onset 12 29
Kanner's Syndrome 12
Childhood Autism 12
Infantile Autism 12
Autistic 52

Characteristics:

HPO:

32
autistic disorder:
Inheritance heterogeneous multifactorial inheritance sporadic
Onset and clinical course childhood onset


Classifications:



Summaries for Autistic Disorder

Disease Ontology : 12 An autism spectrum disorder that is characterized by symptoms across all three symptom domains (communication, social, restricted repetitive interests and behaviors), delayed language development, and symptom onset prior to age 3 years.

MalaCards based summary : Autistic Disorder, also known as autism, is related to pervasive developmental disorder and mental retardation with language impairment and with or without autistic features, and has symptoms including seizures, intellectual disability and autism. An important gene associated with Autistic Disorder is CDKL5 (Cyclin Dependent Kinase Like 5), and among its related pathways/superpathways are Serotonergic synapse and Synaptic Neurotransmission Pathways: GABAergic Inhibition. The drugs Valproic Acid and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, brain and testes, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 72 Autism is a neurodevelopmental disorder characterized by impaired social interaction, impaired verbal... more...

Related Diseases for Autistic Disorder

Diseases related to Autistic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 pervasive developmental disorder 31.4 FMR1 FOXP2 HTR7 MECP2 SLC6A4
2 mental retardation with language impairment and with or without autistic features 12.1
3 mental retardation with language impairment and autistic features 11.8
4 conjunctival degeneration 11.1 HTR2A HTR7 SLC6A4
5 neurogenic bladder 11.0 HTR2A HTR7 SLC6A4
6 hyperthyroxinemia 11.0 HTR2A MECP2 SLC6A4
7 keratosis 11.0 HTR2A HTR7 SLC6A4
8 pervasive developmental disorder not otherwise specified 11.0
9 chronic conjunctivitis 11.0 GABRB3 HTR2A RELN SLC6A4
10 conjunctival pigmentation 11.0 HTR7 SLC6A4
11 epileptic encephalopathy, early infantile, 45 10.9 GABRB3 HTR2A HTR7 SLC6A4
12 personality disorder 10.8 FMR1 HTR2A HTR7 MECP2 RELN SLC6A4
13 premature ovarian failure 1 10.8 FMR1 MECP2 SLC6A4
14 erythermalgia, primary 10.8 CDKL5 GABRB3 SCN2A
15 akinetic mutism 10.8 CDKL5 MECP2
16 splenic abscess 10.8 HTR2A SLC6A4
17 familial partial lipodystrophy 10.8 GABRB3 NLGN3 NLGN4X SLC6A4
18 spondylosis 10.8 CDKL5 GABRA5 TSC2
19 craniosynostosis, adelaide type 10.8 FMR1 HTR2A MECP2 SLC6A4
20 roifman-chitayat syndrome 10.8 CDKL5 GABRA5 GABRB3 MECP2 SNRPN
21 autism spectrum disorder 10.7
22 peyronie's disease 10.7 CDKL5 MECP2 SCN2A TSC2
23 spinocerebellar degeneration 10.7 CDKL5 GSPT2 MECP2 SCN2A
24 asperger syndrome susceptibility, x-linked 2 10.7
25 asperger syndrome susceptibility, x-linked 1 10.7
26 angelman syndrome 10.7 GABRA5 GABRB3 SNRPN
27 indeterminate leprosy 10.7 HTR2A HTR7
28 paraphilia disorder 10.5 NLGN3 NLGN4X
29 fainting 10.2 CDKL5 MECP2 SCN2A
30 atypical autism 10.2 CDKL5 EN2 FMR1 FOXP2 GABRB3 MECP2
31 attention deficit-hyperactivity disorder 10.0
32 intellectual disability 9.9
33 schizophrenia 9.9
34 mutism 9.9
35 bipolar disorder 9.8
36 epilepsy 9.7
37 childhood-onset schizophrenia 9.7
38 obsessive-compulsive disorder 9.7
39 cytomegalovirus infection 9.7
40 cerebritis 9.7
41 rubella 9.7
42 sexual disorder 9.7 CADPS2 EN2 FMR1 FOXP2 GABRA5 GABRB3
43 williams-beuren syndrome 9.6
44 ehlers-danlos syndrome 9.6
45 developmental coordination disorder 9.6
46 anorexia nervosa 9.6
47 tuberous sclerosis 9.6
48 mitochondrial disorders 9.6
49 timothy syndrome 9.6
50 anxiety disorder 9.6

Graphical network of the top 20 diseases related to Autistic Disorder:



Diseases related to Autistic Disorder

Symptoms & Phenotypes for Autistic Disorder

Human phenotypes related to Autistic Disorder:

32 (show all 12)
id Description HPO Frequency HPO Source Accession
1 seizures 32 frequent (33%) HP:0001250
2 intellectual disability 32 HP:0001249
3 autism 32 HP:0000717
4 delayed speech and language development 32 HP:0000750
5 lack of spontaneous play 32 HP:0000721
6 inflexible adherence to routines or rituals 32 HP:0000732
7 impaired ability to form peer relationships 32 HP:0000728
8 eeg abnormality 32 frequent (33%) HP:0002353
9 stereotypy 32 HP:0000733
10 impaired use of nonverbal behaviors 32 HP:0000758
11 restrictive behavior 32 HP:0000723
12 increased serum serotonin 32 frequent (33%) HP:0003144

MGI Mouse Phenotypes related to Autistic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 CADPS2 CDKL5 EN2 FMR1 GABRA5 GABRB3
2 growth/size/body region MP:0005378 9.9 SCN2A SLC6A4 SNRPN TSC2 CADPS2 EN2
3 mortality/aging MP:0010768 9.73 ADSL CADPS2 EN2 GABRB3 HTR7 MECP2
4 nervous system MP:0003631 9.44 GABRA5 GABRB3 HTR7 MECP2 NLGN3 RELN

Drugs & Therapeutics for Autistic Disorder

Drugs for Autistic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 396)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2 99-66-1 3121
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
3 Piracetam Approved Phase 4 7491-74-9
4
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
7
Minocycline Approved, Investigational Phase 4,Phase 2,Phase 1 10118-90-8 5281021
8
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
9
Milnacipran Approved Phase 4 92623-85-3 65833
10
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
11
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3 132539-06-1 4585
12
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
13
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
14
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
15
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
16
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
17
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
18
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
19
Choline Approved, Nutraceutical Phase 4 62-49-7 305
20 Etiracetam Investigational Phase 4 33996-58-6
21 Anticonvulsants Phase 4,Phase 3,Phase 2
22 Antimanic Agents Phase 4,Phase 3,Phase 2
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
24 GABA Agents Phase 4,Phase 3,Phase 2
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
27 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antibodies Phase 4,Phase 2
29 gamma-Globulins Phase 4,Phase 2
30 Immunoglobulins Phase 4,Phase 2
31 Immunoglobulins, Intravenous Phase 4,Phase 2
32 Rho(D) Immune Globulin Phase 4,Phase 2
33 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Neuroprotective Agents Phase 4,Phase 2,Phase 3
36 Nootropic Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
40 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Respiratory System Agents Phase 4,Phase 2,Phase 3
48 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 833)

id Name Status NCT ID Phase Drugs
1 Divalproex Sodium ER in Adult Autism Unknown status NCT00211796 Phase 4 Divalproex Sodium ER
2 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
3 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
4 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
5 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Completed NCT01333072 Phase 4 Aripiprazole;Risperidone
6 Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder Completed NCT01227668 Phase 4 Aripiprazole;Placebo
7 A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder Completed NCT00576732 Phase 4 Placebo;Risperidone high dose;Risperidone low dose
8 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
9 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4 Minocycline
10 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
11 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
12 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
13 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
14 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
15 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
16 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
17 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
18 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
19 Methylphenidate Study in Young Children With Developmental Disorders Completed NCT00517504 Phase 4 Methylphenidate
20 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
21 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
22 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
23 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Completed NCT01683565 Phase 4 LCPUFA oil supplement
24 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
25 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Recruiting NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
26 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4 N-Acetyl Cysteine
27 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Enrolling by invitation NCT02940574 Phase 4 Syntocinon (Oxytocin)
28 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4 Natrol
29 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain Terminated NCT01844700 Phase 4 Ziprasidone;aripiprazole, quetiapine, or risperidone
30 Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls Unknown status NCT02568631 Phase 2, Phase 3
31 Valproate Response in Aggressive Autistic Adolescents Unknown status NCT00065884 Phase 3 Valproate
32 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
33 Self-Injury: Diagnosis and Treatment Unknown status NCT00065936 Phase 3 Naltrexone hydrochloride
34 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
35 Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder Completed NCT00873509 Phase 2, Phase 3 Buspirone;Buspirone;Placebo
36 A Trial of CM-AT in Children With Autism- Open Label Extension Study Completed NCT00912691 Phase 3 CM-AT
37 A Trial of CM-AT in Children With Autism Completed NCT00881452 Phase 3 CM-AT;Placebo
38 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00332241 Phase 3 Aripiprazole;Placebo
39 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
40 A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder Completed NCT01617460 Phase 3 Aripiprazole
41 A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder Completed NCT01617447 Phase 3 Placebo of Aripiprazole;Aripiprazole
42 Study of Fluoxetine in Autism Completed NCT00515320 Phase 3 Fluoxetine;Placebo
43 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00337571 Phase 3 Aripiprazole;Placebo
44 Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism Completed NCT01039792 Phase 2, Phase 3 Methyl B12
45 A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder Completed NCT01624675 Phase 3 Risperidone;Placebo
46 Treatment of Autism in Children and Adolescents Completed NCT00005014 Phase 3 Risperidone
47 Lurasidone Pediatric Autism Study Completed NCT01911442 Phase 3 Lurasidone 20 mg daily;Lurasidone;Placebo
48 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3 Galantamine
49 Open-Label Extension Study of Kuvan for Autism Completed NCT00943579 Phase 2, Phase 3 Kuvan®
50 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER

Search NIH Clinical Center for Autistic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Autistic Disorder cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Autistic Disorder:
NU211-01/NC215-01, human umbilical cord mesenchymal stem cells for autism
Embryonic/Adult Cultured Cells Related to Autistic Disorder:
Umbilical cord-derived mesenchymal stem cells
Umbilical cord blood-derived mononuclear cells

Cochrane evidence based reviews: autistic disorder

Genetic Tests for Autistic Disorder

Genetic tests related to Autistic Disorder:

id Genetic test Affiliating Genes
1 Autistic Disorder of Childhood Onset 29
2 Autism 29
3 Autistic Disorder 24 SNRPN

Anatomical Context for Autistic Disorder

MalaCards organs/tissues related to Autistic Disorder:

39
Brain, Testes, Eye, Bone, Bone Marrow, Cortex, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Autistic Disorder:
id Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Autistic Disorder

Articles related to Autistic Disorder:

(show top 50) (show all 424)
id Title Authors Year
1
An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. ( 28941259 )
2017
2
Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study. ( 28070266 )
2017
3
Evidence of a reduction over time in the behavioral severity of autistic disorder diagnoses. ( 28102641 )
2017
4
A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. ( 27316706 )
2016
5
Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. ( 26659550 )
2016
6
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. ( 27128958 )
2016
7
Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder. ( 27299475 )
2016
8
Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis. ( 27409138 )
2016
9
Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder: A population-based case-control study. ( 27684861 )
2016
10
Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, Gilbert syndrome, and exacerbation of psychosis. ( 26938829 )
2016
11
Female patient with autistic disorder, intellectual disability, and co-morbid anxiety disorder: Expanding the phenotype associated with the recurrent 3q13.2-q13.31 microdeletion. ( 26332054 )
2015
12
Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. ( 25800799 )
2015
13
Risk of cancer in children, adolescents, and young adults with autistic disorder. ( 25453246 )
2015
14
A 6q14.1-q15 microdeletion in a male patient with severe autistic disorder, lack of oral language, and dysmorphic features with concomitant presence of a maternally inherited Xp22.31 copy number gain. ( 26185640 )
2015
15
Kleine-Levin Syndrome in an 8-Year-Old Girl with Autistic Disorder: Does Autism Account a Primary or Secondary Cause? ( 26664444 )
2015
16
Brief Report: Parent-Reported Problems Related to Communication, Behavior and Interests in Children with Autistic Disorder and Their Impact on Quality of Life. ( 26438642 )
2015
17
Pilot Study and Review: Physiological Differences in BDNF, a Potential Biomarker in Males and Females with Autistic Disorder. ( 26866045 )
2015
18
Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study. ( 26538787 )
2015
19
Predictors of quality of life for fathers and mothers of children with Autistic Disorder. ( 24704547 )
2014
20
Psychosocial correlates of parenting a child with autistic disorder. ( 24731972 )
2014
21
Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study. ( 24701014 )
2014
22
Ramelteon monotherapy for insomnia and impulsive behavior in high-functioning autistic disorder. ( 24717259 )
2014
23
Validation of the World Health Organization's Quality of Life Questionnaire with parents of children with autistic disorder. ( 24696377 )
2014
24
Autism Detection in Early Childhood (ADEC): reliability and validity data for a Level 2 screening tool for autistic disorder. ( 24490680 )
2014
25
A randomised group comparison controlled trial of 'preschoolers with autism': A parent education and skills training intervention for young children with autistic disorder. ( 22987897 )
2014
26
HPA and SAM axis responses as correlates of self- vs parental ratings of anxiety in boys with an Autistic Disorder. ( 24412722 )
2014
27
Low rates of depressed mood and depression diagnoses in a clinic review of children and adolescents with autistic disorder. ( 25198799 )
2014
28
Association of 5-HT2A receptor gene polymorphisms with gastrointestinal disorders in Egyptian children with autistic disorder. ( 25462508 )
2014
29
A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. ( 24502859 )
2014
30
The melatonin receptor agonist ramelteon effectively treats insomnia and behavioral symptoms in autistic disorder. ( 24955274 )
2014
31
Smiling response, stranger anxiety, and autistic disorder. ( 23872942 )
2014
32
Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. ( 25118082 )
2014
33
Autistic disorder in Nigeria: Profile and challenges to management. ( 25240124 )
2014
34
Risk of autistic disorder after exposure to general anaesthesia and surgery: A nationwide, retrospective matched cohort study. ( 25101714 )
2014
35
Sedation using 5% lidocaine patches, midazolam and propofol in a combative, obese adolescent with severe autistic disorder undergoing brain magnetic resonance imaging: a case report. ( 25558344 )
2014
36
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. ( 24350813 )
2013
37
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. ( 23212807 )
2013
38
Varenicline in autistic disorder: hypothesis and case report of single-patient crossover. ( 23350866 )
2013
39
Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. ( 22999292 )
2013
40
Maternal prenatal folic acid supplementation is associated with a reduction in development of autistic disorder. ( 23796343 )
2013
41
Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder. ( 24052275 )
2013
42
Parasympathetic response profiles related to social functioning in young children with autistic disorder. ( 24175094 )
2013
43
Biological and psychological rhythms: An integrative approach to rhythm disturbances in autistic disorder. ( 23542543 )
2013
44
Transcranial Direct Current Stimulation for Autistic Disorder. ( 24342925 )
2013
45
Psychometric properties of the Parenting Stress Index with parents of children with autistic disorder. ( 23701497 )
2013
46
Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. ( 23585028 )
2013
47
Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. ( 23821414 )
2013
48
Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. ( 23504356 )
2013
49
Quality of life among parents of children with autistic disorder: A sample from the Arab world. ( 24316492 )
2013
50
Motor stereotypies and volumetric brain alterations in children with Autistic Disorder. ( 23637709 )
2013

Variations for Autistic Disorder

ClinVar genetic disease variations for Autistic Disorder:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CDKL5 NM_003159.2(CDKL5): c.183delT (p.Met63Cysfs) deletion Pathogenic rs62643608 GRCh37 Chromosome X, 18593511: 18593511
2 SCN2A NM_001040142.1(SCN2A): c.2229_2230delAC (p.Lys743Asnfs) deletion Pathogenic rs1057518658 GRCh38 Chromosome 2, 165331409: 165331410
3 GSPT2 NM_018094.4(GSPT2): c.1021G> A (p.Val341Ile) single nucleotide variant Pathogenic rs1057519440 GRCh37 Chromosome X, 51487743: 51487743

Copy number variations for Autistic Disorder from CNVD:

7 (show top 50) (show all 2458)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13764 1 1 28000000 Loss Autism
2 13902 1 10075582 11158005 Loss Autism
3 14098 1 103956056 104113271 Copy number Autism
4 14424 1 108105015 108110680 Gain VAV3 Autism
5 14687 1 109988334 109993086 Deletion or duplication Autism
6 14934 1 111291266 111291409 Loss C1orf103 Autism
7 15234 1 113734887 113735415 Loss MAGI3 Autism
8 15682 1 1180538 1207334 Copy number SDF4 Autism
9 15693 1 118296377 118296518 Gain WDR3 Autism
10 15989 1 1207568 1210341 Copy number B3GALT6 Autism
11 16771 1 1370430 1429557 Loss ATAD3B Autism
12 17284 1 142400000 148000000 Deletion Autism
13 17305 1 142400000 148000000 Duplication Autism
14 17328 1 142400000 148000000 Microdeletions and microduplications Autism
15 17370 1 142600000 147000000 Copy number Autism
16 17384 1 142600000 147000000 Deletion or duplication Autism
17 17385 1 142600000 147000000 Deletion or duplication Autism
18 18034 1 143650000 145000000 Loss Autism
19 18128 1 144124744 144396898 Loss Autism
20 18204 1 144337336 144456849 Gain Autism
21 18273 1 144838594 146308287 Gain BCL9 Autism
22 18300 1 144943150 145824905 Duplication ACP6 Autism
23 18301 1 144943150 145824905 Duplication BCL9 Autism
24 18302 1 144943150 145824905 Duplication CHD1L Autism
25 18303 1 144943150 145824905 Duplication FMO5 Autism
26 18304 1 144943150 145824905 Duplication GJA5 Autism
27 18305 1 144943150 145824905 Duplication PRKAB2 Autism
28 18318 1 144970329 145863421 Duplication Autism
29 18333 1 145013719 146293282 Loss Autism
30 18374 1 145119362 145761156 Gain Autism
31 18390 1 145303997 145357746 Deletion Autism
32 18391 1 145303997 145357746 Homozyg deletion Autism
33 19042 1 148307246 148307430 Gain VPS45 Autism
34 19443 1 150322696 150327314 Copy number S100A5 Autism
35 19590 1 150822223 150852849 Loss LCE3B Autism
36 19591 1 150822223 150852849 Loss LCE3C Autism
37 19764 1 151240762 151240937 Loss SPRR3 Autism
38 19944 1 152055312 152055457 Loss GATAD2B Autism
39 21488 1 1590917 1590971 Gain CDC2L1 Autism
40 22564 1 167493526 167507362 Loss NME7 Autism
41 23029 1 170820885 170824528 Gain C1orf9 Autism
42 23630 1 172142024 172310899 Gain RC3H1 Autism
43 23754 1 173697478 174026214 Gain TNR Autism
44 24014 1 174300000 178600000 Duplication PAPPA2 Autism
45 24015 1 174300000 178600000 Duplication RFWD2 Autism
46 24028 1 174500555 174543675 Duplication PAPPA2 Autism
47 24029 1 174500555 174543675 Duplication RFWD2 Autism
48 24297 1 178294383 178599040 Loss Autism
49 24421 1 180110206 180266346 Loss Autism
50 24441 1 180626647 180627201 Loss GLUL Autism

Expression for Autistic Disorder

Search GEO for disease gene expression data for Autistic Disorder.

Pathways for Autistic Disorder

Pathways related to Autistic Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.31 GABRB3 HTR2A HTR7 SLC6A4
2 10.39 GABRA5 GABRB3
3 10.25 HTR2A HTR7 SLC6A4

GO Terms for Autistic Disorder

Cellular components related to Autistic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.88 CADPS2 FMR1 GABRA5 GABRB3 NLGN3 NLGN4X
2 integral component of plasma membrane GO:0005887 9.86 GABRA5 GABRB3 HTR2A HTR7 NLGN3 NLGN4X
3 dendrite GO:0030425 9.72 FMR1 GABRA5 HTR2A NLGN4X RELN
4 presynapse GO:0098793 9.54 CADPS2 FMR1 SLC6A4
5 GABA-A receptor complex GO:1902711 9.43 GABRA5 GABRB3
6 postsynaptic membrane GO:0045211 9.35 CADPS2 FMR1 GABRA5 GABRB3 NLGN4X
7 postsynapse GO:0098794 9.33 FMR1 MECP2 NLGN3
8 synapse GO:0045202 9.17 CADPS2 CDKL5 FMR1 GABRA5 GABRB3 NLGN3

Biological processes related to Autistic Disorder according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.86 GABRA5 HTR2A HTR7 MECP2
2 memory GO:0007613 9.67 HTR2A MECP2 SLC6A4
3 innervation GO:0060384 9.62 GABRA5 GABRB3
4 smooth muscle contraction GO:0006939 9.61 HTR2A HTR7
5 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.61 NLGN3 RELN
6 neuron development GO:0048666 9.61 EN2 GABRA5 GABRB3
7 vasoconstriction GO:0042310 9.6 HTR7 SLC6A4
8 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.59 NLGN3 RELN
9 neuron cell-cell adhesion GO:0007158 9.58 NLGN3 NLGN4X
10 vocalization behavior GO:0071625 9.58 NLGN3 NLGN4X
11 cerebellum development GO:0021549 9.58 FOXP2 MECP2 NLGN4X
12 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.57 MECP2 NLGN3
13 negative regulation of neuron apoptotic process GO:0043524 9.56 EN2 GABRA5 GABRB3 MECP2
14 negative regulation of excitatory postsynaptic potential GO:0090394 9.55 NLGN3 NLGN4X
15 brain development GO:0007420 9.55 GABRA5 MECP2 RELN SCT SLC6A4
16 presynaptic membrane assembly GO:0097105 9.54 NLGN3 NLGN4X
17 regulation of behavior GO:0050795 9.52 HTR2A RELN
18 inner ear receptor cell development GO:0060119 9.51 GABRA5 GABRB3
19 long-term synaptic potentiation GO:0060291 9.5 MECP2 NLGN3 RELN
20 inhibitory postsynaptic potential GO:0060080 9.48 GABRB3 NLGN3
21 positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity GO:2000969 9.37 NLGN3 RELN
22 learning GO:0007612 9.26 MECP2 NLGN3 NLGN4X RELN
23 postsynaptic membrane assembly GO:0097104 9.16 NLGN3
24 social behavior GO:0035176 8.92 MECP2 NLGN3 NLGN4X SLC6A4

Molecular functions related to Autistic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 GABA-A receptor activity GO:0004890 9.26 GABRA5 GABRB3
2 neurexin family protein binding GO:0042043 9.16 NLGN3 NLGN4X
3 serotonin binding GO:0051378 8.96 HTR2A HTR7
4 siRNA binding GO:0035197 8.62 FMR1 MECP2

Sources for Autistic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....